McKenna's Pharmacology for Nursing, 2e

985

Index

clinical presentation, 232–233 histamine release, 231 kinin system, 231

Interneurons, 385, 386 Interstitial cells, 596, 601, 602 Interstitial cystitis, 819, 827 Intestine, hormones and, 514 Intractable hiccough, 929, 932 Intravenous regional local anaesthesia, 425 Intravenous solutions dosage calculations, 56–57 Intrinsic pathway, 750, 751, 753 Iodine, 551, 950 Iodine solutions, 552 adverse effects, 561 drug–drug interactions, 561 pharmacokinetics, 560 therapeutic actions and indications, 560 Ion transporters, 17 Ipratropium, 501–503, 864, 867, 873–874, 875 Irbesartan, 665, 669 Irinotecan, 222 Iron therapeutic effect, 5 toxicity, 784–785 Iron-deficiency anaemia, 774, 776 agents used to treat, 782–787 adverse effects, 783 care considerations, 786–787 contraindications and cautions, 783 drug–drug interactions, 783–784 drug–food interactions, 784 pharmacokinetics, 783 therapeutic actions and indications, 782–783 Iron polymaltose, 782–783 Iron sucrose, 782 Irritable bowel syndrome, 926–927 drugs, 916, 927 Isoflurane, 416, 420, 422, 423 Isoniazid, 91, 118, 119, 120 Isoprenaline, 455, 465–466, 676 Isosorbide dinitrate, 716–718 Isosorbide mononitrate, 716–718 Isotonic solution, 77 Isotretanoin, 953 Isradipine, 665, 671 Itraconazole, 151–154 Ivermectin, 183, 185 J Jambul, 965 Japanese encephalitis vaccine, 280 Java plum, 471, 965 Jojoba, 965 Journals, 12 Juniper berries, 582, 965 K Kava, 965 Ketamine, 67, 420, 421 Ketoconazole, 151–154, 157, 951 Ketoprofen, 241, 247 Ketorolac, 241, 247, 957 Ketosis, 572, 576 Ketotifen, 957

Kidneys, 795–800 blood pressure control, 799 blood supply, 796

Infliximab, 265, 266 Influenza A and respiratory viruses, 126, 127, 130–132 adverse effects, 131

calcium regulation, 799 chloride regulation, 798 countercurrent mechanism, 797–798 damage, 86 glomerular filtration, 797 hormones and, 514 maintenance of body fluids, 797–799 nephron, 794, 795–797 potassium regulation, 798 regulation of red blood cell production, 799–800 sodium regulation, 797 structure, 795–796 tubular reabsorption, 797

care considerations, 131–132 contraindications and cautions, 130–131 drug–drug interactions, 131

pharmacokinetics, 130 therapeutic actions and

contraindications, 129, 130 Influenza virus vaccines, 274, 280 H1N1 pandemic, 2809t Inhibin, 596, 602 Inorganic compounds, 5 Insulin, 572–593 adverse effects, 581 care considerations, 582–583 contraindications and cautions, 579, 581 delivery, 580, 581 diabetes mellitus (type I), 584–585 drug–drug interactions, 581–582 name confusion, 579 pharmacokinetics, 579 therapeutic actions and indications, 579, 581 Integrase inhibitor, 126, 136, 141–142 Intellectual functions, 300 Intensives Medicines Monitoring Programme (IMMP), 65 Interactions, 25, 27–28 drug–drug or drug–alternative therapy, 27–28 drug–food, 28 drug–laboratory test, 28 Interferon alfa-2a, 259, 261 Interferon alfa-2b, 258, 259, 261 Interferon beta-1a, 259, 261 Interferon beta-1b, 259, 261 Interferon gamma-1b, 259, 260, 261 Interferons, 126, 127, 228, 235, 259–261 adverse effects, 261 care considerations, 262–263 contraindications and cautions, 260 drug–drug interactions, 261 pharmacokinetics, 260 therapeutic actions and indications, 259–260 Interleukin-receptor antagonist, 266 adverse effects, 266 care considerations, 267–268 contraindications and cautions, 266 pharmacokinetics, 266 therapeutic actions and indications, 266 Interleukins, 228, 235, 261–262 adverse effects, 262 care considerations, 262–263 contraindications and cautions, 262 pharmacokinetics, 262 therapeutic actions and indications, 261–262 Internet information, 12, 60, 61–62

tubular secretion, 797 Kinin system, 228, 231 Kudzu, 966 L Labels, 11

Labetalol, 469, 470, 472, 676 Lacosamide, 354, 365–367 Lactulose, 919, 920 Lamivudine, 136, 137, 139 Lamotrigine, 154, 344, 345, 354, 365–367 Lanreotide, 525, 528–529 Lansoprazole, 900, 906–907 Lapatinib, 219, 220, 221 Laryngitis, 838 Larynx, 834, 835, 836 Latanoprost, 957 Lavender, 966 Laxatives, 916, 917–922 adults, 917

bulk stimulants, 916, 919, 920 care considerations, 921–922 chemical stimulant, 916, 918–919 children, 917 lubricants, 916, 920–921 older adults, 917 opioid-induced constipation, 405 LDLs (low-density lipoproteins), 729, 732 Ledum tincture, 966 Leflunomide, 253, 254–255 Leishmaniasis, 163, 171 Lepirudin, 757, 766 Leprostatic drugs, 118–121 adverse effects, 119–120 care considerations, 120–121 contraindications and cautions, 119 drug–drug interactions, 120 pharmacokinetics, 119 therapeutic actions and indications, 118–119 Lercanidipine, 666, 671 Letrozole, 212, 214 Leucovorin, 203, 787 Leukocytes, 228, 230 Leukotriene receptor antagonists, 864, 865, 877, 878–880 adverse effects, 878–879 care considerations, 879–880